A small but growing number of addiction medicine physicians have begun recommending kratom, a plant-based substance derived from the leaves of Mitragyna speciosa, as a harm-reduction tool for patients struggling with opioid dependence — and the practice has ignited one of the most bitter debates in addiction medicine in years. These doctors argue that kratom’s partial opioid receptor activity can ease withdrawal symptoms and reduce cravings without the regulatory barriers and stigma attached to medications like methadone and buprenorphine, pointing to patients who have used it to step down from fentanyl or heroin when other options failed or were inaccessible. Dr. Mark Sullivan, a psychiatrist at Yale who has studied alternative approaches to opioid use disorder, has noted that some patients arrive at his clinic already self-treating with kratom, and a subset of them appear to have genuinely stabilized their lives.
On the other side, a larger contingent of addiction specialists, pharmacologists, and public health officials view kratom prescribing as reckless and dangerous. Their objections are grounded in kratom’s lack of FDA approval, its unpredictable potency across commercial products, documented cases of liver toxicity and seizures, and a rising number of kratom-associated deaths — the CDC linked kratom to 152 overdose fatalities between 2016 and 2017 alone. For families navigating dementia caregiving, where a loved one may also have a history of substance use or chronic pain management challenges, this debate is far from academic. This article examines what kratom actually does in the brain, why the medical community is so divided, what the evidence actually shows, and what caregivers and patients should know before considering it as part of any treatment plan.
Table of Contents
- Why Are Some Addiction Doctors Turning to Kratom Despite the Controversy?
- What Kratom Actually Does to the Brain — And Why That Matters for Cognitive Health
- The Unregulated Market Problem and Contamination Risks
- How Kratom Compares to FDA-Approved Addiction Treatments
- Dependence, Withdrawal, and the Myth of the “Natural” Free Pass
- Legal Status and the Patchwork of State Regulations
- Where the Research Is Heading — And What Caregivers Should Watch For
- Conclusion
- Frequently Asked Questions
Why Are Some Addiction Doctors Turning to Kratom Despite the Controversy?
The doctors who have cautiously incorporated kratom into their practices tend to share a common frustration: the existing system for treating opioid use disorder is failing too many people. Methadone requires daily visits to a licensed clinic, which can be impossible for patients in rural areas or those without transportation. Buprenorphine, while more accessible since the elimination of the X-waiver requirement in 2023, still faces prescriber shortages and insurance barriers. For patients who have tried and failed these options — or who refuse them due to stigma — some clinicians see kratom as a flawed but pragmatic alternative to continued illicit opioid use. The pharmacology offers a partial rationale. Kratom’s primary active alkaloids, mitragynine and 7-hydroxymitragynine, bind to mu-opioid receptors in a manner somewhat analogous to buprenorphine, acting as partial agonists.
At low doses, users report mild stimulant effects and pain relief. At higher doses, the effects become more sedating and opioid-like. Proponents argue this profile gives kratom a ceiling effect that makes fatal respiratory depression less likely than with full agonist opioids like fentanyl, though this claim remains contested by toxicologists. A 2020 study published in drug and Alcohol Dependence surveyed over 2,800 kratom users and found that a majority reported using it to reduce or eliminate opioid use, with many describing improvements in mood and daily functioning. However, the physicians who recommend kratom are quick to emphasize that they are not endorsing the gas station capsules or head shop powders that constitute most of the commercial kratom market. They typically work with patients who source from specific vendors with third-party testing, use standardized dosing protocols, and undergo regular monitoring — conditions that are essentially impossible to replicate at scale without regulatory infrastructure that does not currently exist.
What Kratom Actually Does to the Brain — And Why That Matters for Cognitive Health
Kratom’s interaction with the brain extends well beyond the opioid system, and this is where the conversation becomes particularly relevant for anyone concerned about dementia, neurodegeneration, or long-term cognitive function. In addition to opioid receptors, mitragynine interacts with adrenergic, serotonergic, and dopaminergic pathways. This polypharmacology means that kratom is not simply a “natural opioid” — it is a complex psychoactive substance whose full neurological impact remains poorly characterized. For older adults or individuals with early cognitive decline, this complexity is a serious concern. Chronic opioid receptor activation has been associated with cognitive impairment in multiple studies, including reduced processing speed, impaired working memory, and changes in white matter integrity.
A 2019 study in Neuroscience and Biobehavioral Reviews found that long-term opioid use was associated with deficits in attention and executive function that persisted even after cessation. While kratom is pharmacologically distinct from classical opioids, there is no evidence that it is exempt from these risks, and some preliminary animal research suggests that chronic mitragynine exposure may affect hippocampal function. However, if someone is choosing between continued fentanyl use and kratom, the calculus changes significantly. Fentanyl’s risks — overdose death, hypoxic brain injury, infectious complications from injection — are catastrophic and immediate. In this narrow context, kratom may represent a less dangerous alternative, even if it carries its own cognitive risks. The problem is that this harm-reduction argument can easily be stretched beyond its legitimate scope, used to justify kratom consumption by people who are not facing a fentanyl-or-nothing choice but who have simply found a legal substance that makes them feel good.
The Unregulated Market Problem and Contamination Risks
One of the most concrete dangers of kratom has nothing to do with the plant itself and everything to do with how it reaches consumers. Because kratom is sold as a dietary supplement or botanical product rather than a pharmaceutical, it is not subject to the manufacturing standards, potency testing, or contamination screening required of prescription medications. Independent laboratory analyses have repeatedly found alarming inconsistencies in commercial kratom products. A 2019 investigation by the fda found that multiple kratom products were contaminated with heavy metals, including lead and nickel, at levels exceeding safe exposure thresholds. Separate testing by independent labs has identified kratom products adulterated with synthetic opioids, benzodiazepines, and even fentanyl — the very substance many users are trying to avoid.
In 2018, a multistate salmonella outbreak was traced to contaminated kratom, sickening nearly 200 people across 41 states. For an older adult with compromised immune function, or a dementia patient whose caregiver might be considering kratom for agitation or pain management, these contamination risks are not hypothetical. The American Kratom Association, an industry advocacy group, has pushed for Good Manufacturing Practice standards through its GMP Standards Program, and some vendors voluntarily submit to third-party testing. But participation is not mandatory, enforcement is nonexistent, and the vast majority of kratom sold in convenience stores, gas stations, and online marketplaces has no meaningful quality assurance. A patient who reads about kratom’s potential benefits and purchases a random product from the internet is not receiving the same substance that was used in the clinical scenarios described by its medical advocates.
How Kratom Compares to FDA-Approved Addiction Treatments
Understanding where kratom fits — or fails to fit — alongside established treatments requires an honest comparison. Methadone, buprenorphine, and naltrexone are the three FDA-approved medications for opioid use disorder, and each has decades of clinical trial data supporting its efficacy. Methadone reduces opioid mortality by approximately 50 percent, and buprenorphine shows similar benefits with a more favorable safety profile. Naltrexone, an opioid antagonist, works differently by blocking the effects of opioids entirely, but adherence is a persistent challenge. Kratom has none of this evidentiary foundation. There are no completed randomized controlled trials comparing kratom to placebo or to existing medications for opioid use disorder. The evidence base consists primarily of self-report surveys, case series, preclinical animal studies, and observational data from Southeast Asia, where kratom has been used traditionally for centuries. While these sources suggest biological plausibility, they do not meet the standard required for a clinical recommendation.
The gap between “some patients report it helped them” and “this is a safe and effective treatment” is vast, and it is precisely the gap that clinical trials are designed to bridge. The tradeoff for patients is real, though. Buprenorphine requires a prescription and pharmacy access. Methadone demands daily clinic attendance that many working people cannot sustain. Both carry their own side effects, including constipation, sexual dysfunction, and cognitive fog. Kratom is legal in most states, available without a prescription, and relatively inexpensive. For someone without insurance, in a treatment desert, who has been through multiple failed treatment attempts, the practical advantages are obvious — even if the medical evidence is insufficient. The question is whether the medical establishment can find a way to study kratom rigorously enough to either validate or reject it, rather than simply condemning its use while offering no viable alternative to the patients who are already taking it.
Dependence, Withdrawal, and the Myth of the “Natural” Free Pass
One of the most persistent and dangerous misconceptions about kratom is that because it comes from a plant, it is inherently safe or non-addictive. This is flatly wrong. Kratom produces physical dependence with regular use, and withdrawal symptoms — which include muscle aches, insomnia, irritability, nausea, diarrhea, and intense cravings — can be severe enough to drive continued use even when a person wants to stop. Case reports in the medical literature describe patients who escalated from a few grams daily to thirty or forty grams, developed tolerance, and found themselves in a cycle of dependence that mirrored the opioid addiction they were trying to escape. A 2014 study of regular kratom users in Malaysia found that more than half met criteria for moderate to severe dependence, and withdrawal symptoms typically began within twelve to twenty-four hours of the last dose. In the United States, poison control centers have seen a dramatic increase in kratom-related calls, rising from 26 in 2006 to over 1,800 in 2017.
For caregivers managing a loved one with dementia who also has a pain condition or substance use history, introducing another dependency-forming substance — especially one without standardized dosing or medical oversight — adds complexity and risk to an already difficult situation. The “natural” framing also ignores that many of the most dangerous substances in pharmacology are plant-derived. Morphine comes from poppies. Cocaine comes from coca leaves. Nicotine comes from tobacco. The botanical origin of a compound tells you absolutely nothing about its safety profile, its addictive potential, or its appropriateness for medical use. Any clinician or advocate who leans on the “natural” argument to reassure patients about kratom’s safety is either uninformed or being deliberately misleading.
Legal Status and the Patchwork of State Regulations
Kratom’s legal status in the United States is a confusing patchwork that makes informed decision-making even harder. At the federal level, kratom is legal but has been the subject of repeated regulatory actions. The FDA has issued multiple warnings, the DEA considered scheduling it as a controlled substance in 2016 but reversed course after public backlash, and several states have enacted their own bans.
As of early 2026, kratom is banned in Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin, while other states have passed the Kratom Consumer Protection Act, which regulates rather than prohibits the substance by requiring labeling, age restrictions, and contamination testing. For families in states where kratom remains unregulated, the absence of legal restrictions does not equate to safety. It means that there is no governmental body ensuring that what is in the package matches what is on the label, no system for reporting adverse events, and no prescriber who can be held accountable if something goes wrong. This regulatory vacuum is particularly concerning for vulnerable populations, including elderly individuals with polypharmacy risks and cognitive impairment that may limit their ability to research products or recognize adverse effects.
Where the Research Is Heading — And What Caregivers Should Watch For
The National Institute on Drug Abuse has funded several research initiatives to better characterize kratom’s pharmacology and therapeutic potential, and at least two academic centers are working toward clinical trials that could begin in the next few years. Researchers at the University of Florida and the University of Rochester have been studying mitragynine analogs that might retain the beneficial properties — pain relief and withdrawal suppression — while reducing abuse potential and toxicity. If these efforts succeed, the result could be a new class of atypical opioid medications that owes its existence to kratom research without requiring patients to consume unregulated plant material.
In the meantime, caregivers and patients should approach kratom claims with the same skepticism they would apply to any unregulated supplement marketed with dramatic testimonials but limited clinical data. If a loved one with dementia or cognitive impairment is experiencing pain, agitation, or a co-occurring substance use disorder, evidence-based treatments exist and should be pursued first. If kratom is already being used, disclosure to all treating physicians is essential, as kratom can interact with numerous medications — including several commonly prescribed in dementia care, such as certain antidepressants and antipsychotics — through cytochrome P450 enzyme inhibition.
Conclusion
The kratom debate in addiction medicine is not a simple story of enlightened doctors versus backward regulators, nor is it a story of reckless practitioners endangering patients with snake oil. It is a conflict rooted in genuine failures of the existing treatment system, legitimate pharmacological curiosity, real risks from an unregulated market, and an evidence base that is suggestive but far from conclusive. For the subset of patients who have exhausted other options and are using kratom under medical supervision with quality-tested products, the practice may represent a reasonable harm-reduction strategy.
For everyone else, the risks — contamination, dependence, drug interactions, cognitive effects — remain poorly quantified and potentially serious. For caregivers navigating the intersection of dementia, chronic pain, and substance use, the most important steps are to maintain open communication with the care team, insist on evidence-based treatments as first-line options, and resist the allure of any substance marketed as a natural cure-all. If kratom eventually proves its worth through rigorous clinical trials, that will be a genuine advance. Until then, caution is not conservatism — it is the only responsible position when the stakes are someone’s brain.
Frequently Asked Questions
Is kratom legal everywhere in the United States?
No. As of 2026, kratom is banned in six states — Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin — and several cities and counties have enacted local bans. In states where it is legal, regulation varies widely, and legality does not imply safety or quality assurance.
Can kratom interact with dementia medications?
Yes. Kratom inhibits several cytochrome P450 enzymes, which are responsible for metabolizing many common medications, including certain antidepressants, antipsychotics, and cholinesterase inhibitors used in dementia treatment. These interactions can lead to elevated drug levels and increased side effects. Always disclose kratom use to the prescribing physician.
Is kratom safer than prescription opioids?
The evidence is insufficient to make that claim definitively. While kratom may have a lower risk of fatal respiratory depression compared to full agonist opioids like fentanyl, it carries its own risks including dependence, liver toxicity, seizures, and contamination in unregulated products. It has not undergone the controlled testing required to establish a reliable safety profile.
Can kratom cause cognitive decline?
There is limited but concerning evidence. Chronic activation of opioid receptors has been associated with cognitive impairment in multiple studies, and preliminary animal research suggests that long-term mitragynine exposure may affect memory-related brain regions. No long-term human studies on kratom’s cognitive effects have been completed.
Should a caregiver ever give kratom to a dementia patient?
This is not recommended. Dementia patients are particularly vulnerable to drug interactions, unpredictable dosing, and adverse cognitive effects. Any pain or agitation management should be discussed with the patient’s medical team and should rely on treatments with established safety data.
